Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$32.2 - $43.61 $483,000 - $654,150
15,000 New
15,000 $572,000
Q4 2021

Feb 15, 2022

SELL
$37.06 - $47.11 $207,536 - $263,816
-5,600 Reduced 8.67%
59,000 $2.51 Million
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $4.56 Million - $6.25 Million
64,600 New
64,600 $4.84 Million
Q1 2019

May 14, 2019

SELL
$89.33 - $163.65 $267,990 - $490,950
-3,000 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$81.94 - $139.71 $245,820 - $419,130
3,000 New
3,000 $287,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Sg3 Management, LLC Portfolio

Follow Sg3 Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg3 Management, LLC with notifications on news.